OCGN upgraded to buy

$NRX Pharmaceuticals (NRXP.US)$ Here is why OCGN will skyrocket 400% to 800% over the next 9 to 12 months.

What is OCU400's market potential? If we take Ocugen's estimates seriously, it is mouthwatering. The biotech projects that OCU400 could earn approval in 2026. Ocugen thinks the therapy could generate between $30 billion and $47 billion in total revenue in the five years after approval. The company's market cap is about $488 million as of this writing. So by any standard, if these projections work out, Ocugen is severely undervalued.

And that's without considering the rest of the company's pipeline. The biotech is developing OCU410 as a potential treatment for dry age-related macular degeneration, another eye-related disease. Ocugen projects sales of $75 billion in the first five years for OCU410, which is currently in phase 1/2 testing.

I didn't sell at $2 because I'm holding for $10 or more. $500 million dollar market cap, and a potential market on FDA approval for $200 billion on their strong pipeline.

Buy and hold....look at the chart I posted, look at how strong it is....Google price targets for OCGN....once you do the DD then buy this.

Shorts are trapped that's why they are trying to file a bogus lawsuit to cover 55 million shares...they are trapped blow $1